Literature DB >> 26304897

Effectiveness and Cost Effectiveness of Bevacizumab in Metastatic Colorectal Cancer.

Andrea Messori1, Mauro De Rosa2, Valeria Fadda3, Luca Pani4.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26304897     DOI： 10.1200/JCO.2015.61.8991

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Comment on: "Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review".

Authors:  Angelo Claudio Palozzo; Andrea Messori
Journal:  Pharmacoeconomics       Date:  2016-04       Impact factor: 4.981

2.  Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX.

Authors:  Erik van Dijk; Erik van Werkhoven; Rebecca Asher; Jennifer K Mooi; David Espinoza; Hendrik F van Essen; Harm van Tinteren; Nicole C T van Grieken; Cornelis J A Punt; Niall C Tebbutt; Bauke Ylstra
Journal:  Int J Cancer       Date:  2022-05-23       Impact factor: 7.316

3.  Fatty acid synthase regulates invasion and metastasis of colorectal cancer via Wnt signaling pathway.

Authors:  Haiyu Wang; Qiulei Xi; Guohao Wu
Journal:  Cancer Med       Date:  2016-05-03       Impact factor: 4.452
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.